Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.

<h4>Background</h4>Despite the fact that direct oral anticoagulants (DOACs) are favoured over warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), physicians need to maintain competence in using and monitoring warfarin since many patients have contrain...

Full description

Bibliographic Details
Main Authors: Rita Selby, Lisa Kaus, Faith Sealey, Marika Koo, Sameer Parpia, Brian Chan, Soo Jin Seung, Carole Bradley, Rachel Strauss, Nicole Mittmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0284425
_version_ 1797839148437995520
author Rita Selby
Lisa Kaus
Faith Sealey
Marika Koo
Sameer Parpia
Brian Chan
Soo Jin Seung
Carole Bradley
Rachel Strauss
Nicole Mittmann
author_facet Rita Selby
Lisa Kaus
Faith Sealey
Marika Koo
Sameer Parpia
Brian Chan
Soo Jin Seung
Carole Bradley
Rachel Strauss
Nicole Mittmann
author_sort Rita Selby
collection DOAJ
description <h4>Background</h4>Despite the fact that direct oral anticoagulants (DOACs) are favoured over warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), physicians need to maintain competence in using and monitoring warfarin since many patients have contraindications or other barriers to using DOACs. Unlike DOACs, warfarin therapy requires regular blood testing to ensure that it is within a target range to ensure efficacy and safety. There is limited real-world data on the adequacy of warfarin control and the cost and burden of monitoring warfarin therapy in Canadian NVAF patients.<h4>Objectives</h4>In a large cohort of Canadian patients with NVAF on warfarin we assessed time in therapeutic range (TTR), determinants of TTR, process of care, direct costs, health related quality of life and loss of work time and productivity related to warfarin therapy.<h4>Methods</h4>Five hundred and fifty one patients with NVAF, either newly initiated or stable on warfarin were prospectively enrolled across 9 Canadian provinces from primary care practices and anticoagulant clinics. Participating physicians provided baseline demographic and medical information. Patients completed diaries for 48 weeks, capturing information about International Normalized Ratio (INR) test results, test locations, process of INR monitoring, direct costs of travel, health-related quality of life and work productivity measures. TTR was estimated using linear interpolation of INR results and linear regression used to investigate associations between TTR and factors (defined a priori).<h4>Results</h4>Four hundred and eighty (87.1%) patients had complete follow-up with an overall TTR of 74.4% based on 7,175 physician-reported INR values from 501 patients. 88% of this cohort were monitored through routine medical care (RMC). The average number of INRs per patient during the 48-week period was 14.1 (standard deviation (SD) = 8.3) tests with a mean duration of 23.8 (SD = 11.1) days between tests. We did not find a relationship between TTR and age, sex, presence of major comorbidities, patient's province of residence or rural vs. urban residence. 12% of patients monitored through anticoagulant clinics had significantly better TTR than patients monitored through RMC (82% vs. 74%; 95% confidence interval: -13.8, -1.2; p = 0.02). Health related quality of life utility values were high and remained consistent throughout the study. The majority of patients reported no impact on either work productivity or impairment of regular activities due to being on long-term warfarin treatment.<h4>Conclusions</h4>We showed excellent overall TTR in an observed Canadian cohort, with monitoring through a dedicated anticoagulant clinic being associated with a statistically and clinically significant improvement in TTR. The burden of warfarin therapy on patients' health related quality of life or daily work and activities was low.
first_indexed 2024-04-09T15:53:31Z
format Article
id doaj.art-e40026a9cfe54f6e9d8ea28cef6c7d1d
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-09T15:53:31Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-e40026a9cfe54f6e9d8ea28cef6c7d1d2023-04-26T05:31:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01184e028442510.1371/journal.pone.0284425Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.Rita SelbyLisa KausFaith SealeyMarika KooSameer ParpiaBrian ChanSoo Jin SeungCarole BradleyRachel StraussNicole Mittmann<h4>Background</h4>Despite the fact that direct oral anticoagulants (DOACs) are favoured over warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), physicians need to maintain competence in using and monitoring warfarin since many patients have contraindications or other barriers to using DOACs. Unlike DOACs, warfarin therapy requires regular blood testing to ensure that it is within a target range to ensure efficacy and safety. There is limited real-world data on the adequacy of warfarin control and the cost and burden of monitoring warfarin therapy in Canadian NVAF patients.<h4>Objectives</h4>In a large cohort of Canadian patients with NVAF on warfarin we assessed time in therapeutic range (TTR), determinants of TTR, process of care, direct costs, health related quality of life and loss of work time and productivity related to warfarin therapy.<h4>Methods</h4>Five hundred and fifty one patients with NVAF, either newly initiated or stable on warfarin were prospectively enrolled across 9 Canadian provinces from primary care practices and anticoagulant clinics. Participating physicians provided baseline demographic and medical information. Patients completed diaries for 48 weeks, capturing information about International Normalized Ratio (INR) test results, test locations, process of INR monitoring, direct costs of travel, health-related quality of life and work productivity measures. TTR was estimated using linear interpolation of INR results and linear regression used to investigate associations between TTR and factors (defined a priori).<h4>Results</h4>Four hundred and eighty (87.1%) patients had complete follow-up with an overall TTR of 74.4% based on 7,175 physician-reported INR values from 501 patients. 88% of this cohort were monitored through routine medical care (RMC). The average number of INRs per patient during the 48-week period was 14.1 (standard deviation (SD) = 8.3) tests with a mean duration of 23.8 (SD = 11.1) days between tests. We did not find a relationship between TTR and age, sex, presence of major comorbidities, patient's province of residence or rural vs. urban residence. 12% of patients monitored through anticoagulant clinics had significantly better TTR than patients monitored through RMC (82% vs. 74%; 95% confidence interval: -13.8, -1.2; p = 0.02). Health related quality of life utility values were high and remained consistent throughout the study. The majority of patients reported no impact on either work productivity or impairment of regular activities due to being on long-term warfarin treatment.<h4>Conclusions</h4>We showed excellent overall TTR in an observed Canadian cohort, with monitoring through a dedicated anticoagulant clinic being associated with a statistically and clinically significant improvement in TTR. The burden of warfarin therapy on patients' health related quality of life or daily work and activities was low.https://doi.org/10.1371/journal.pone.0284425
spellingShingle Rita Selby
Lisa Kaus
Faith Sealey
Marika Koo
Sameer Parpia
Brian Chan
Soo Jin Seung
Carole Bradley
Rachel Strauss
Nicole Mittmann
Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
PLoS ONE
title Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
title_full Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
title_fullStr Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
title_full_unstemmed Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
title_short Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
title_sort quality of anticoagulant control and patient experience associated with long term warfarin in canadian patients with non valvular atrial fibrillation a multicentre prospective study
url https://doi.org/10.1371/journal.pone.0284425
work_keys_str_mv AT ritaselby qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT lisakaus qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT faithsealey qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT marikakoo qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT sameerparpia qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT brianchan qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT soojinseung qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT carolebradley qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT rachelstrauss qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy
AT nicolemittmann qualityofanticoagulantcontrolandpatientexperienceassociatedwithlongtermwarfarinincanadianpatientswithnonvalvularatrialfibrillationamulticentreprospectivestudy